Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Res. 2019 Oct 16;18(1):166–178. doi: 10.1158/1541-7786.MCR-19-0204

Figure 6: PRMT6/ILF2 signaling axis regulates the expression of MIF.

Figure 6:

A. Lysates of Beas2B cells expressing either control or HA-ILF2 were screened for differentially expressing cytokines by using a human cytokine array as described in the methods. B. Expression of ICAM1, IL8, IL32, and MIF transcripts in Beas2B cells expressing either control or HA-ILF2 using qPCR. *, p< 0.05; **, p< 0.01; versus control. C. Beas2B cells were transfected with either control or HA-ILF2. The cell lysates were later probed for the expression of ILF2 and MIF via immunoblotting. D, E. Lysates of H2122 (D) and H1299 (E) transfected with ILF2-specific siRNAs were immunoblotted with anti-ILF2 and anti-MIF antibodies. F, G. Lysates of H2122 (F) and H1299 (G) PRMT6 knockout clones and their parental cells were immunoblotted with anti-PRMT6, anti-ILF2, and anti-MIF antibodies. H. Tissue lysates from the lungs of PRMT6Tg; Sftpc-Cretm and PRMT6Tg control mice after tamoxifen and urethane treatments were subjected to immunoblotting with anti-PRMT6, anti-ILF2, and anti-MIF antibodies. I. Beas2B cell lysates co-transfected with HA-PRMT6 plasmid with either control or ILF2 siRNAs were probed for the expression of HA-PRMT6, ILF2, and MIF via immunoblotting. J-L. The proliferation rates of Beas2B cells co-transfected with HA-ILF2 plasmid with either control or MIF siRNAs were determined by hematocytometer cell count (K) and clonogenic (L) cell proliferation assays as described in the methods. **, p< 0.01. The cell lysates were later probed for the expression of HA-ILF2, and MIF via immunoblotting (J).